Santhera Starting Phase 1b/2a Trial Testing Potential CF therapy POL6014
Oct 31, 2018 08:00 am | Ana Pena
A Phase 1b/2a, dose-escalating clinical trial evaluating the effects of POL6014 in patients with cystic fibrosis (CF) was recently launched, according to Santhera Pharmaceuticals, developer of the investigational therapy. The Phase 1b/2a (EudraCT 2016-005110-22) will evaluate the safety, tolerability, pharmacokinetics (drug absorption, distribution, and elimination by the body), and pharmacodynamics (the drug’s effects) of orally inhaled […]
The post Santhera Starting Phase 1b/2a Trial Testing Potential CF therapy POL6014 appeared first on Cystic Fibrosis News Today. |
|
|
Why Are Our Doctors Not Discussing Herbal Supplements with Us?
Oct 30, 2018 09:00 am | Brad Dell
The 2018 North American Cystic Fibrosis Conference (NACFC) in Denver was rad, huh? The Cystic Fibrosis Foundation (CFF) is making great strides in the inclusion of patient voices, which has led to a selection of initiatives based on our feedback. Over the next five years, the foundation will invest $100 million in infection research. Wow. The conference also […]
The post Why Are Our Doctors Not Discussing Herbal Supplements with Us? appeared first on Cystic Fibrosis News Today. |
|
|
VX-445 Triple Combo Improves Lung Function in CF Patients with F508del Mutations, Phase 2 Trial Shows
Oct 30, 2018 08:30 am | Ana Pena
Adding the investigational therapy VX-445 to tezacaftor (VX-661) and Kalydeco (ivacaftor) led to a roughly 10 percent improvement in the lung function of cystic fibrosis (CF) patients with F508del mutations in the CFTR gene in a proof-of-concept Phase 2 clinical trial. The treatment was effective in patients with one or two F508del copies (the most common CF-causing mutation), and has […]
The post VX-445 Triple Combo Improves Lung Function in CF Patients with F508del Mutations, Phase 2 Trial Shows appeared first on Cystic Fibrosis News Today. |
|
|
|
A Phase 1b/2a, dose-escalating clinical trial evaluating the effects of POL6014 in patients with cystic fibrosis (CF) was recently launched, according to Santhera Pharmaceuticals, developer of the investigational therapy. The Phase 1b/2a (EudraCT 2016-005110-22) will evaluate the safety, tolerability, pharmacokinetics (drug absorption, distribution, and elimination by the body), and pharmacodynamics (the drug’s effects) of orally inhaled […]
The 2018 North American Cystic Fibrosis Conference (NACFC) in Denver was rad, huh? The Cystic Fibrosis Foundation (CFF) is making great strides in the inclusion of patient voices, which has led to a selection of initiatives based on our feedback. Over the next five years, the foundation will invest $100 million in infection research. Wow. The conference also […]
Adding the investigational therapy VX-445 to tezacaftor (VX-661) and Kalydeco (ivacaftor) led to a roughly 10 percent improvement in the lung function of cystic fibrosis (CF) patients with F508del mutations in the CFTR gene in a proof-of-concept Phase 2 clinical trial. The treatment was effective in patients with one or two F508del copies (the most common CF-causing mutation), and has […]
No hay comentarios:
Publicar un comentario